|
Market Closed -
OTC Markets
12:10:26 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 0.7547 USD | +11.10% |
|
+0.00% | -15.49% |
| 10-09 | GF Securities Starts CStone Pharmaceuticals at Buy with HK$11.56 Price Target | MT |
| 09-24 | CStone Pharma CEO Buys HK$2.7 Million of Shares | MT |
Company Valuation: CStone Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,845 | 4,882 | 2,628 | 2,759 | 6,980 | 6,915 | - | - |
| Change | - | -37.77% | -46.18% | 4.99% | 153.01% | -0.94% | - | - |
| Enterprise Value (EV) 1 | 7,249 | 4,551 | 1,950 | 2,404 | 6,404 | 5,937 | 2,892 | 2,743 |
| Change | - | -37.22% | -57.15% | 23.28% | 166.37% | -7.29% | -51.29% | -5.16% |
| P/E | - | -5.32x | -7.11x | -30.9x | -15.3x | -15x | 4.06x | 31x |
| PBR | 6.63x | 10.9x | 5.7x | - | 10.7x | - | - | - |
| PEG | - | - | 0.1x | 0.4x | -0x | 2.33x | -0x | -0.4x |
| Capitalization / Revenue | 32.2x | 10.1x | 5.67x | 6.78x | 25.9x | 16.3x | 4.01x | 7.23x |
| EV / Revenue | 29.7x | 9.45x | 4.2x | 5.9x | 23.8x | 14x | 1.68x | 2.87x |
| EV / EBITDA | -3.99x | -5.1x | -3.33x | -25.9x | -16.5x | -14.7x | 1.49x | 12.9x |
| EV / EBIT | -3.96x | -4.99x | -3.22x | -22.7x | -14.8x | -15.6x | 2.63x | -34.9x |
| EV / FCF | -4.57x | -7.43x | - | - | -19.5x | -18.9x | -14.6x | -22.3x |
| FCF Yield | -21.9% | -13.5% | - | - | -5.12% | -5.29% | -6.85% | -4.48% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.77 | -0.29 | -0.07 | -0.31 | -0.29 | 1.07 | 0.14 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 243.7 | 481.4 | 463.8 | 407.2 | 269.6 | 423.2 | 1,722 | 956.2 |
| EBITDA 1 | -1,818 | -892.9 | -585.4 | -92.72 | -388.6 | -405.2 | 1,937 | 212.3 |
| EBIT 1 | -1,829 | -912.1 | -605.6 | -106.1 | -432.6 | -381 | 1,102 | -78.51 |
| Net income 1 | -1,920 | -902.7 | -367.2 | -91.21 | -437 | -383.5 | 680.5 | -48.57 |
| Net Debt 1 | -596.2 | -331.1 | -677.7 | -354.7 | -576.3 | -977.7 | -4,023 | -4,172 |
| Reference price 2 | 6.737 | 4.096 | 2.061 | 2.161 | 4.736 | 4.344 | 4.344 | 4.344 |
| Nbr of stocks (in thousands) | 1,164,452 | 1,192,099 | 1,275,317 | 1,276,503 | 1,473,942 | 1,591,633 | - | - |
| Announcement Date | 6/8/22 | 4/26/23 | 4/23/24 | 3/27/25 | 3/26/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.21x | 12.07x | 24.51x | 0.59% | 1,043B | |
| 28.53x | 6.31x | 18.08x | 2.08% | 618B | |
| 34.51x | 8.02x | 16.59x | 2.55% | 481B | |
| 103.58x | 5.8x | 24.76x | 2.4% | 351B | |
| 19.03x | 4.65x | 11.56x | 2.84% | 338B | |
| 19.78x | 5.2x | 12.8x | 3.06% | 269B | |
| 20.32x | 4.17x | 11.93x | 2.13% | 244B | |
| 25.73x | 6.72x | 11.97x | 2.48% | 220B | |
| -44.49x | 6.55x | 25.51x | 2.24% | 182B | |
| Average | 26.69x | 6.61x | 17.52x | 2.26% | 416.3B | |
| Weighted average by Cap. | 31.90x | 7.75x | 18.94x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 2616 Stock
- CSPHF Stock
- Valuation CStone Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
